-
Something wrong with this record ?
Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation
MC. Operti, A. Bernhardt, V. Sincari, E. Jager, S. Grimm, A. Engel, M. Hruby, CG. Figdor, O. Tagit
Language English Country Switzerland
Document type Journal Article
Grant support
PRECIOUS 686089
European Union
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
Despite the efficacy and potential therapeutic benefits that poly(lactic-co-glycolic acid) (PLGA) nanomedicine formulations can offer, challenges related to large-scale processing hamper their clinical and commercial development. Major hurdles for the launch of a polymeric nanocarrier product on the market are batch-to-batch variations and lack of product consistency in scale-up manufacturing. Therefore, a scalable and robust manufacturing technique that allows for the transfer of nanomedicine production from the benchtop to an industrial scale is highly desirable. Downstream processes for purification, concentration, and storage of the nanomedicine formulations are equally indispensable. Here, we develop an inline sonication process for the production of polymeric PLGA nanomedicines at the industrial scale. The process and formulation parameters are optimized to obtain PLGA nanoparticles with a mean diameter of 150 ± 50 nm and a small polydispersity index (PDI < 0.2). Downstream processes based on tangential flow filtration (TFF) technology and lyophilization for the washing, concentration, and storage of formulations are also established and discussed. Using the developed manufacturing and downstream processing technologies, production of two PLGA nanoformulations encasing ritonavir and celecoxib was achieved at 84 g/h rate. As a measure of actual drug content, encapsulation efficiencies of 49.5 ± 3.2% and 80.3 ± 0.9% were achieved for ritonavir and celecoxib, respectively. When operated in-series, inline sonication and TFF can be adapted for fully continuous, industrial-scale processing of PLGA-based nanomedicines.
Evonik Corporation Birmingham Laboratories Birmingham AL 35211 USA
Evonik Operations GmbH Research Development and Innovation 64293 Darmstadt Germany
Institute of Macromolecular Chemistry CAS Heyrovsky Square 2 162 06 Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010161
- 003
- CZ-PrNML
- 005
- 20220425131732.0
- 007
- ta
- 008
- 220420s2022 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics14020276 $2 doi
- 035 __
- $a (PubMed)35214009
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Operti, Maria Camilla $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany $1 https://orcid.org/0000000222176096
- 245 10
- $a Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation / $c MC. Operti, A. Bernhardt, V. Sincari, E. Jager, S. Grimm, A. Engel, M. Hruby, CG. Figdor, O. Tagit
- 520 9_
- $a Despite the efficacy and potential therapeutic benefits that poly(lactic-co-glycolic acid) (PLGA) nanomedicine formulations can offer, challenges related to large-scale processing hamper their clinical and commercial development. Major hurdles for the launch of a polymeric nanocarrier product on the market are batch-to-batch variations and lack of product consistency in scale-up manufact $a Despite the efficacy and potential therapeutic benefits that poly lactic co glycolic acid PLGA nanomedicine formulations can offer challenges related to large scale processing hamper their clinical and commercial development Major hurdles for the launch of a polymeric nanocarrier product on the market are batch to batch variations and lack of product consistency in scale up manufacturing $a Despite the efficacy and potential therapeutic benefits that poly(lactic-co-glycolic acid) (PLGA) nanomedicine formulations can offer, challenges related to large-scale processing hamper their clinical and commercial development. Major hurdles for the launch of a polymeric nanocarrier product on the market are batch-to-batch variations and lack of product consistency in scale-up manufacturing. Therefore, a scalable and robust manufacturing technique that allows for the transfer of nanomedicine production from the benchtop to an industrial scale is highly desirable. Downstream processes for purification, concentration, and storage of the nanomedicine formulations are equally indispensable. Here, we develop an inline sonication process for the production of polymeric PLGA nanomedicines at the industrial scale. The process and formulation parameters are optimized to obtain PLGA nanoparticles with a mean diameter of 150 ± 50 nm and a small polydispersity index (PDI < 0.2). Downstream processes based on tangential flow filtration (TFF) technology and lyophilization for the washing, concentration, and storage of formulations are also established and discussed. Using the developed manufacturing and downstream processing technologies, production of two PLGA nanoformulations encasing ritonavir and celecoxib was achieved at 84 g/h rate. As a measure of actual drug content, encapsulation efficiencies of 49.5 ± 3.2% and 80.3 ± 0.9% were achieved for ritonavir and celecoxib, respectively. When operated in-series, inline sonication and TFF can be adapted for fully continuous, industrial-scale processing of PLGA-based nanomedicines.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bernhardt, Alexander $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
- 700 1_
- $a Sincari, Vladimir $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic $1 https://orcid.org/000000027379066X
- 700 1_
- $a Jager, Eliezer $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic
- 700 1_
- $a Grimm, Silko $u Evonik Operations GmbH, Research Development & Innovation, 64293 Darmstadt, Germany
- 700 1_
- $a Engel, Andrea $u Evonik Corporation, Birmingham Laboratories, Birmingham, AL 35211, USA
- 700 1_
- $a Hruby, Martin $u Institute of Macromolecular Chemistry CAS, Heyrovsky Square 2, 162 06 Prague, Czech Republic $1 https://orcid.org/000000025075261X $7 xx0060770
- 700 1_
- $a Figdor, Carl Gustav $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
- 700 1_
- $a Tagit, Oya $u Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands $1 https://orcid.org/0000000257736647
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 14, č. 2 (2022)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35214009 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220420 $b ABA008
- 991 __
- $a 20220425131729 $b ABA008
- 999 __
- $a ind $b bmc $g 1784510 $s 1161359
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 2 $e 20220125 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a PRECIOUS 686089 $p European Union
- LZP __
- $a Pubmed-20220420